Sweden
· Delayed Price · Currency is SEK Dicot Pharma AB Statistics
Total Valuation
Dicot Pharma AB has a market cap or net worth of SEK 1.33 billion. The enterprise value is 1.22 billion.
| Market Cap | 1.33B |
| Enterprise Value | 1.22B |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Dicot Pharma AB has 2.01 billion shares outstanding.
| Current Share Class | 2.01B |
| Shares Outstanding | 2.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.23% |
| Owned by Institutions (%) | 14.00% |
| Float | 1.68B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 12.49 |
| P/TBV Ratio | 12.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.65 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.86
| Current Ratio | 9.86 |
| Quick Ratio | 9.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8,057.90 |
Financial Efficiency
Return on equity (ROE) is -126.21% and return on invested capital (ROIC) is -81.39%.
| Return on Equity (ROE) | -126.21% |
| Return on Assets (ROA) | -68.90% |
| Return on Invested Capital (ROIC) | -81.39% |
| Return on Capital Employed (ROCE) | -75.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -19.52M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +116.33% in the last 52 weeks. The beta is 1.66, so Dicot Pharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | +116.33% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 51.04 |
| Average Volume (20 Days) | 9,892,832 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -80.58M |
| Pretax Income | -78.10M |
| Net Income | -78.10M |
| EBITDA | -80.57M |
| EBIT | -80.58M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 105.80 million in cash and n/a in debt, giving a net cash position of 105.80 million or 0.05 per share.
| Cash & Cash Equivalents | 105.80M |
| Total Debt | n/a |
| Net Cash | 105.80M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 106.30M |
| Book Value Per Share | 0.05 |
| Working Capital | 106.30M |
Cash Flow
| Operating Cash Flow | -78.17M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Dicot Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -5.88% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |